asciminib
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Pressure score
55
Momentum score
51
Why This Matters
Roche is a direct competitive threat because it is already approved in Hematology · Chronic Myeloid Leukemia (asciminib) and could narrow Novartis's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Approved
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Moderate share risk if competitor advances before the signal sponsor establishes label leadership.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Neurology · Autoimmune Disease · Trial Update · This positions ENSPRYNG as a potential first-line treatment for MOGAD, a disease with no current approved therapies, impacting the competitive landscape significantly.
Source: Roche
View source documentRelated Signal
Novartis initiates pediatric study for asciminib in Chronic Myeloid Leukemia
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #3 of 3
Lilly
1 competitive finding
Top program: asciminib
- Pressure
- 75
- Momentum
- 51
- Threat
- regulatory competitor
- Stage
- Approved
75LillyHighasciminib·Approved
Bristol Myers Squibb
1 competitive finding
Top program: asciminib
- Pressure
- 58
- Momentum
- 14
- Threat
- emerging competitor
- Stage
- Phase I
58Bristol Myers SquibbMediumasciminib·Phase I
Roche
2 competitive findings
Top program: asciminib
- Pressure
- 55
- Momentum
- 51
- Threat
- direct competitor
- Stage
- Approved
55RocheMediumasciminib·Approved